Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia
Recruitment status was: Active, not recruiting
|Pick Disease of the Brain||Radiation: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)||Phase 1|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Management, Control and Treatment of Frontotemporal Dementia (Pick's Disease)|
- Therapy for FTD patients [ Time Frame: 1 year ]
- Rehabilitation of FTD Patients [ Time Frame: 1 Year ]
|Study Start Date:||May 2008|
|Estimated Study Completion Date:||October 2009|
|Estimated Primary Completion Date:||May 2009 (Final data collection date for primary outcome measure)|
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Radiation: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Other Name: Far Infrared Radiation (5μm to 20μm wavelength)
This disorder causes progressive destruction of nerve cells in the brain and causes tau proteins to accumulate into the "Pick bodies" that are a defining characteristic of the disease. Tau proteins are microtubule-associated proteins that are abundant in neurons in the central nervous system and are less common elsewhere.
Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.
It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have FTD.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00674960
|The Centre for Incurable Diseases|
|Toronto, Ontario, Canada, M4V 1L5|
|Principal Investigator:||Ken Nedd, M.D.||GAAD Medical Research Institute Inc.|